

Development of a Novel Chromatographic Method for Analysis of Drugs and Pharmaceutical Formulations

Zain Ul Bashar Khan¹, Dr. K. Manjuladevi²

¹Research Scholar, School of Pharmaceutical Sciences, VISTAS, Chennai - 600 117, India

²Associate Professor, Department of Pharmacology School of Pharmaceutical Sciences, VISTAS, Chennai - 600 117

Abstract: *Chromatographic techniques represent the cornerstone of pharmaceutical analysis, providing essential tools for quality control, drug development, and regulatory compliance. The continuous evolution of drug molecules and formulation complexity necessitates the development of novel, efficient, and robust analytical methods. This review comprehensively examines the principles, development strategies, and validation protocols associated with modern chromatographic methods for pharmaceutical analysis. The article explores various chromatographic techniques including High Performance Liquid Chromatography (HPLC), Ultra Performance Liquid Chromatography (UPLC), Gas Chromatography (GC), and hyphenated methods, emphasizing their applications in drug and formulation analysis [1,2]. Key aspects of method development such as stationary phase selection, mobile phase optimization, and detection strategies are discussed in detail. The review highlights validation parameters as per International Conference on Harmonisation (ICH) guidelines, ensuring method reliability and regulatory acceptance [3]. Recent advances including green chromatography, miniaturized techniques, and the integration of artificial intelligence in method optimization are examined [4,5]. Challenges related to instrumentation costs, matrix interference, and method reproducibility are addressed alongside future perspectives on sustainable and automated analytical solutions. This comprehensive review serves as a valuable resource for pharmaceutical scientists, analytical chemists, and researchers engaged in developing innovative chromatographic methods for contemporary pharmaceutical challenges.*

Keywords: Chromatographic method development, pharmaceutical analysis, HPLC, method validation, ICH guidelines, drug formulations, analytical techniques

1. Introduction

The pharmaceutical industry operates under stringent regulatory frameworks that demand precise, accurate, and reliable analytical methods for drug quality assessment. Pharmaceutical analysis encompasses the identification, quantification, and characterization of active pharmaceutical ingredients (APIs) and their formulations throughout the drug development lifecycle [6]. Among various analytical techniques available, chromatography has emerged as the most versatile and widely adopted methodology for pharmaceutical applications.

Chromatographic methods offer exceptional separation efficiency, sensitivity, and specificity, making them indispensable for analyzing complex pharmaceutical matrices [7]. The ability to separate, identify, and quantify multiple components simultaneously has positioned chromatography as the gold standard in pharmaceutical quality control laboratories worldwide. Regulatory authorities including the United States Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO) require validated chromatographic methods for drug approval and quality monitoring [8].

The development of a novel chromatographic method involves systematic optimization of multiple parameters including column chemistry, mobile phase composition, detection wavelength, flow rate, and temperature [10]. Each parameter significantly influences separation efficiency, peak resolution, and method sensitivity. A scientifically sound approach to method development ensures reproducibility, robustness, and regulatory compliance.

This review aims to provide a comprehensive understanding of chromatographic method development for pharmaceutical analysis. The objectives include examining various chromatographic techniques, discussing systematic method development strategies, reviewing validation protocols, exploring contemporary applications, and identifying future trends in pharmaceutical chromatography. This article serves as a practical guide for researchers and analysts involved in developing innovative analytical solutions for pharmaceutical quality assurance.

2. Overview of Chromatographic Techniques

2.1 High- Performance Liquid Chromatography (HPLC)

High- Performance Liquid Chromatography represents the most extensively utilized technique in pharmaceutical laboratories. HPLC operates on the principle of differential partitioning between a mobile liquid phase and a stationary solid phase [11]. The technique offers remarkable versatility, accommodating various separation modes including reversed-phase, normal-phase, ion-exchange, and size-exclusion chromatography.

Reversed-phase HPLC (RP-HPLC) dominates pharmaceutical applications, utilizing nonpolar stationary phases such as octadecylsilane (C18) or octylsilane (C8) bonded to silica particles. The mobile phase typically consists of aqueous buffers combined with organic modifiers like methanol, acetonitrile, or tetrahydrofuran [12].

Modern HPLC systems incorporate advanced features including gradient elution capabilities, temperature control,

autosampler functionality, and sophisticated detection systems. Common detectors include ultraviolet-visible (UV-Vis) detectors, photodiode array (PDA) detectors, fluorescence detectors, and refractive index detectors [13].

The selection of appropriate detection mode depends on analyte properties and sensitivity requirements. Table 1 presents a comparison of major chromatographic techniques used in pharmaceutical analysis.

Table 1: Comparison of Major Chromatographic Techniques in Pharmaceutical Analysis

Technique	Mobile Phase	Typical Applications	Advantages	Limitations
HPLC	Liquid	General drug analysis, impurities, stability	Versatile, robust, widely validated	Moderate resolution, longer analysis time
UPLC	Liquid	High-throughput, trace analysis	High resolution, fast, sensitive	High cost, specialized equipment
GC	Gas	Volatile compounds, residual solvents	Excellent resolution, sensitive	Limited to volatile/thermostable analytes
TLC/HPTLC	Liquid	Screening, identity tests, herbal drugs	Low cost, simple, multiple samples	Limited quantitation accuracy
LC-MS	Liquid	Impurity identification, bioanalysis	Structural information, highly sensitive	Very high cost, complex operation
GC-MS	Gas	Volatiles identification, metabolites	Definitive identification, sensitive	Requires derivatization for many drugs

2.2 Ultra Performance Liquid Chromatography (UPLC)

Ultra Performance Liquid Chromatography represents a significant advancement in liquid chromatography technology. UPLC systems operate at substantially higher pressures (up to 15,000 psi) compared to conventional HPLC (up to 6,000 psi), enabling the use of sub-two-micron particle columns [14]. This technological enhancement delivers superior resolution, sensitivity, and analysis speed.

The reduced particle size in UPLC columns increases surface area, improving mass transfer kinetics and separation efficiency. Typical UPLC methods achieve analysis times three to five times faster than equivalent HPLC methods while consuming significantly less solvent [15]. This efficiency translates to reduced operational costs and environmental impact, aligning with green chemistry principles.

UPLC particularly benefits pharmaceutical applications requiring high-throughput screening, impurity profiling, and bioanalytical quantification. The enhanced sensitivity enables detection and quantification of trace-level impurities and degradation products, critical for pharmaceutical quality control and stability studies [16].

2.3 Gas Chromatography (GC)

Gas Chromatography serves as the preferred technique for analyzing volatile and thermally stable pharmaceutical compounds. GC separates components based on their vapor pressure and interaction with the stationary phase at elevated temperatures [17]. The technique offers exceptional resolution, sensitivity, and reproducibility for suitable analytes.

Common GC applications in pharmaceutical analysis include residual solvent determination, volatile impurity analysis, and quantification of volatile APIs. Capillary columns with various stationary phase chemistries provide versatile separation capabilities. Popular stationary phases include polysiloxanes, polyethylene glycols, and specialized phases for chiral separations [18].

Detection systems for GC include flame ionization detectors (FID), thermal conductivity detectors (TCD), electron capture detectors (ECD), and nitrogen-phosphorus detectors (NPD). The choice of detector depends on analyte properties and regulatory requirements [17].

2.4 Thin Layer Chromatography (TLC) and High-Performance Thin Layer Chromatography (HPTLC)

Thin Layer Chromatography offers a simple, cost-effective approach for pharmaceutical analysis. TLC provides rapid qualitative screening, identity testing, and purity assessment [19].

Modern HPTLC instruments incorporate automated sample application, controlled development, and densitometric detection, enhancing reproducibility and quantitative capabilities.

HPTLC advantages include minimal sample preparation, simultaneous analysis of multiple samples, and lower solvent consumption compared to column chromatography. The technique proves particularly valuable for preliminary method development, herbal drug analysis, and quality control in resource-limited settings [20].

2.5 Hyphenated Techniques

Hyphenated chromatographic techniques combine separation power with spectroscopic or spectrometric detection, providing comprehensive structural and quantitative information [21]. Liquid Chromatography-Mass Spectrometry (LC-MS) and Gas Chromatography-Mass Spectrometry (GC-MS) represent the most important hyphenated techniques in pharmaceutical analysis.

LC-MS combines HPLC separation with mass spectrometric detection, offering unparalleled sensitivity and specificity. The technique enables molecular weight determination, structural elucidation, and trace-level quantification [22]. Various ionization modes including electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) accommodate diverse compound classes.

GC-MS provides definitive identification of volatile compounds through spectral library matching. The technique

excels in residual solvent analysis, impurity identification, and metabolite characterization [23]. Tandem mass spectrometry (MS/MS) further enhances selectivity and sensitivity, particularly valuable for complex biological matrices.

3. Development of Novel Chromatographic Methods

3.1 Selection of Stationary Phase

Stationary phase selection represents the foundation of chromatographic method development. The choice depends on analyte properties including polarity, ionization state, molecular weight, and thermal stability [24]. For HPLC applications, reversed-phase columns with C18 or C8 bonding remain the primary choice for neutral and weakly acidic or basic compounds.

Particle size significantly influences separation efficiency and analysis time. Traditional five-micron particles provide

adequate resolution with moderate back pressure, while sub-two-micron particles offer superior efficiency at the cost of increased system pressure requirements [25]. Three-micron particles often represent an optimal compromise between efficiency and practicality.

Column dimensions including length, internal diameter, and particle porosity require careful consideration. Longer columns generally provide better resolution but increase analysis time and solvent consumption [26]. Narrower columns enhance mass sensitivity but demand precise flow control and minimal extra-column band broadening.

Specialized stationary phases address specific analytical challenges. Phenyl-bonded phases improve aromatic compound retention and selectivity. Amino and cyano phases support normal-phase separations. Chiral stationary phases enable enantiomer separation, critical for pharmaceutical applications given regulatory requirements regarding stereoisomeric purity [27].

Table 2: Common Stationary Phases and Their Applications in Pharmaceutical Analysis

Stationary Phase	Polarity	Typical Applications	Suitable Compounds	pH Range
C18 (ODS)	Nonpolar	General purpose, reversed-phase	Moderately polar to nonpolar drugs	2.0-8.0
C8 (Octyl)	Nonpolar	Hydrophobic compounds	Nonpolar drugs, lipids	2.0-8.0
Phenyl	Moderately polar	Aromatic compounds	Aromatic drugs, isomers	2.0-7.5
Cyano (CN)	Polar	Normal-phase, polar compounds	Polar drugs, vitamins	2.0-7.5
Amino (NH ₂)	Polar	Carbohydrates, polar compounds	Sugars, polar metabolites	2.0-7.0
Silica	Highly polar	Normal-phase separations	Fat-soluble vitamins, lipids	2.0-7.0
Chiral phases	Variable	Enantiomer separation	Chiral drugs, optical isomers	Variable

3.2 Mobile Phase Optimization

Mobile phase composition critically influences retention, selectivity, and peak shape. For reversed-phase chromatography, the mobile phase typically comprises an aqueous buffer combined with an organic modifier [28]. Common organic modifiers include methanol, acetonitrile, and tetrahydrofuran, each offering distinct selectivity characteristics.

Acetonitrile provides superior UV transparency and lower viscosity compared to methanol, enabling higher flow rates and lower column back pressure [29]. Methanol offers different selectivity patterns and proves more environmentally friendly and cost-effective. The choice between solvents depends on analyte properties, separation requirements, and practical considerations.

Gradient elution allows systematic variation of mobile phase composition during analysis, accommodating compounds with widely varying polarities. Gradient optimization involves defining initial and final organic content, gradient slope, and equilibration time [30]. Well-designed gradients ensure adequate resolution while minimizing analysis time.

Isocratic elution maintains constant mobile phase composition throughout analysis, offering simplicity and superior reproducibility. This approach suits samples with similar polarity ranges and remains preferred for routine quality control applications [11].

3.3 pH and Buffer Selection

Solution pH profoundly affects ionizable compound retention and peak shape. Most pharmaceutical compounds contain acidic or basic functional groups that ionize depending on solution pH relative to their dissociation constants (pK_a values) [31]. Optimizing pH based on analyte pK_a enables control over ionization state and chromatographic behavior.

For acidic compounds, maintaining pH at least two units below the pK_a ensures predominantly protonated, neutral forms that retain well on reversed-phase columns. Conversely, basic compounds require pH values at least two units above their pK_a for optimal retention as neutral species [32].

Buffer selection involves considering buffering capacity, UV transparency, compatibility with detection methods, and regulatory acceptability. Common buffers include phosphate, acetate, formate, and ammonium salts [33]. Buffer concentration typically ranges from ten to fifty millimolar, balancing adequate buffering capacity against potential column fouling and MS compatibility issues.

Trifluoroacetic acid (TFA) and formic acid serve as mobile phase additives for acidic compounds, suppressing ionization and improving peak shape. Triethylamine or ammonia solution benefits basic compound analysis through ion-pairing or ion-suppression mechanisms [34].

3.4 Detection Techniques

Detector selection depends on analyte properties, sensitivity requirements, and available instrumentation. UV-Vis detectors remain the most common choice for pharmaceutical analysis due to their versatility, reliability, and regulatory acceptance [35]. Most pharmaceutical compounds contain chromophores that absorb UV light between 190 and 400 nanometers.

Photodiode array (PDA) detectors simultaneously monitor multiple wavelengths, enabling peak purity assessment and spectral confirmation of compound identity. This capability proves invaluable for method validation and routine analysis where co-elution risks exist [13].

Fluorescence detection offers superior sensitivity for compounds with native fluorescence or those amenable to derivatization. The technique provides selectivity advantages in complex matrices, detecting analytes at picogram levels [36].

Refractive index (RI) detectors serve as universal detectors independent of chromophore presence. However, RI detection lacks sensitivity compared to UV detection and proves incompatible with gradient elution [37].

Evaporative light scattering detectors (ELSD) and charged aerosol detectors (CAD) offer universal detection capabilities with gradient compatibility. These mass-sensitive detectors prove particularly valuable for carbohydrates, lipids, and other compounds lacking chromophores [38].

Table 3: Comparison of Detection Systems in Chromatographic Analysis

Detector Type	Detection Principle	Sensitivity	Selectivity	Applications	Limitations
UV-Vis	Absorbance at fixed wavelength	ng-µg range	Moderate	General pharmaceutical analysis	Requires chromophore
PDA	Multi-wavelength absorbance	ng-µg range	High	Peak purity, impurity profiling	Requires chromophore
Fluorescence	Fluorescence emission	pg-ng range	Very high	Bioanalysis, trace analysis	Limited to fluorescent compounds
RI	Refractive index change	µg-mg range	Low	Universal detection	Low sensitivity, no gradient
ELSD	Light scattering	ng-µg range	Moderate	Non-chromophoric compounds	Destructive, requires optimization
CAD	Aerosol charging	ng-µg range	Moderate	Universal, gradient compatible	High cost
MS	Mass-to-charge ratio	pg-fg range	Very high	Structure elucidation, trace analysis	Very high cost, complex

3.5 Method Optimization Strategies

Systematic method optimization employs experimental design approaches to efficiently explore parameter space and identify optimal conditions. Traditional one-factor-at-a-time (OFAT) approaches prove time-consuming and fail to detect interaction effects between variables [39].

Design of Experiments (DoE) methodologies including factorial designs, central composite designs, and Box-Behnken designs enable simultaneous optimization of multiple factors while minimizing experimental runs [40]. These statistical approaches identify significant factors, interaction effects, and optimal operating regions.

Quality by Design (QbD) principles increasingly guide pharmaceutical method development. QbD emphasizes systematic understanding of method variables, risk assessment, and definition of a design space within which method performance remains acceptable [41]. This approach enhances method robustness and facilitates regulatory approval.

4. Validation of Chromatographic Methods

4.1 Regulatory Framework and ICH Guidelines

Method validation provides documented evidence that an analytical procedure consistently produces reliable results suitable for its intended purpose [3]. The International Conference on Harmonisation (ICH) guideline Q2(R1) defines validation requirements for analytical procedures used in pharmaceutical quality assessment. Regulatory authorities worldwide recognize ICH guidelines as the standard for method validation.

Validation parameters include specificity, linearity, range, accuracy, precision, detection limit, quantification limit, and robustness. The extent of validation depends on method purpose, with different requirements for identification tests, quantitative assays, impurity testing, and dissolution studies [43].

Table 4: ICH Q2(R1) Validation Parameters and Acceptance Criteria

Parameter	Definition	Typical Acceptance Criteria	Evaluation Method
Specificity	Ability to assess analyte unequivocally	No interference from impurities/excipients	Forced degradation, blank analysis
Linearity	Proportional response vs. concentration	$r^2 \geq 0.999$, %y-intercept $\leq 2\%$	Minimum 5 concentration levels
Accuracy	Closeness to true value	Recovery: 98-102% (API), 95-105% (formulation)	Triplicate at 3 levels (80%, 100%, 120%)
Precision (Repeatability)	Agreement among repeated measurements	RSD $\leq 2\%$ (API), $\leq 3\%$ (formulation)	Six replicate injections
Intermediate Precision	Day-to-day, analyst-to-analyst variation	RSD $\leq 3\%$	Different day/analyst/equipment

LOD	Lowest detectable concentration	S/N ratio $\geq 3:1$	Signal-to-noise or statistical calculation
LOQ	Lowest quantifiable concentration	S/N ratio $\geq 10:1$, RSD $\leq 10\%$, Recovery 80-120%	Experimental verification at LOQ level
Robustness	Resistance to small parameter variations	Method performance unchanged	Deliberate variation of parameters
Range	Interval between upper and lower limits	80-120% for assay, LOQ-120% for impurities	Covers expected concentrations

4.2 Specificity

Specificity demonstrates the method's ability to unequivocally assess the analyte in the presence of potentially interfering components including impurities, degradation products, and matrix components [44]. For chromatographic methods, specificity evaluation involves demonstrating adequate resolution between the analyte peak and nearest potential interferents.

Specificity assessment typically includes analyzing blank samples, placebo formulations, and samples spiked with known impurities or degradation products. Peak purity evaluation using photodiode array detection or mass spectrometric analysis provides additional specificity confirmation [45].

Forced degradation studies expose drug substances and products to stress conditions including acidic, alkaline, oxidative, thermal, and photolytic environments. Demonstrating that degradation products do not interfere with analyte quantification establishes method stability-indicating capability, a critical requirement for pharmaceutical quality control [46].

4.3 Linearity and Range

Linearity demonstrates that test results are directly proportional to analyte concentration within a defined range [3]. The validation protocol requires preparing at least five concentration levels spanning the expected analytical range. For assay methods, the range typically extends from eighty to one hundred twenty percent of target concentration.

Statistical evaluation of linearity includes calculating the correlation coefficient, y-intercept, slope, and residual analysis. A correlation coefficient exceeding 0.999 generally indicates acceptable linearity [47]. Visual inspection of the calibration plot and residual plots helps identify non-linearity or outliers.

The analytical range represents the interval between lower and upper concentration limits where the method demonstrates acceptable accuracy, precision, and linearity. Range requirements vary with method purpose, with impurity methods requiring wider ranges to accommodate various impurity levels [48].

4.4 Accuracy

Accuracy expresses the closeness of agreement between the measured value and the true or accepted reference value [3]. Accuracy assessment involves analyzing samples of known concentration and comparing obtained results to theoretical values. Typical protocols include analyzing at least nine

determinations across three concentration levels spanning the method range.

Recovery studies provide practical accuracy assessment, particularly for assay methods. Acceptable recovery typically falls within ninety-eight to one hundred two percent of theoretical values for drug substances and ninety-five to one hundred five percent for drug products, depending on analyte concentration levels [49].

For impurity methods, accuracy evaluation involves adding known amounts of impurities to samples and determining recovery. This approach proves particularly valuable when reference standards are unavailable, using the parent compound as a surrogate for impurity quantification [50].

4.5 Precision

Precision evaluates the closeness of agreement between multiple independent measurements obtained under specified conditions [3]. Precision assessment occurs at three levels: repeatability (intra-day precision), intermediate precision (inter-day precision), and reproducibility (inter-laboratory precision).

Repeatability involves analyzing multiple samples of homogeneous material under the same conditions within a short time period. Typically, six replicate determinations at target concentration demonstrate repeatability [51]. Acceptable relative standard deviation (RSD) values generally remain below two percent for drug substances and below three percent for drug products.

Intermediate precision introduces variations in analyst, day, and equipment while maintaining the same laboratory and method. This parameter better reflects real-world method performance and helps establish realistic acceptance criteria for routine analysis [52].

Reproducibility involves validation across different laboratories, typically during collaborative studies or method transfer. This parameter proves particularly relevant for pharmacopeial methods or procedures used across multiple sites [53].

4.6 Limit of Detection and Quantification

The Limit of Detection (LOD) represents the lowest analyte concentration that can be detected but not necessarily quantified [3]. LOD determination employs signal-to-noise ratio approaches or statistical calculations based on calibration curve parameters. A signal-to-noise ratio of three-to-one typically defines LOD.

The Limit of Quantification (LOQ) represents the lowest concentration that can be quantified with acceptable accuracy

and precision. LOQ typically corresponds to a signal-to-noise ratio of ten-to-one [54]. Experimental verification involves analyzing samples at the proposed LOQ level and demonstrating acceptable precision (RSD below ten percent) and accuracy (recovery between eighty and one hundred twenty percent).

For impurity methods, sensitivity requirements depend on impurity classification and regulatory thresholds. ICH guideline Q3A(R2) defines reporting, identification, and qualification thresholds based on maximum daily dose, necessitating methods capable of detecting impurities at or below these levels [55].

5. Application of Chromatographic Methods in Drug and Formulation Analysis

5.1 Bulk Drug Analysis

Chromatographic methods serve as primary tools for active pharmaceutical ingredient (API) quality assessment throughout manufacturing and storage [57]. Assay methods determine API content, ensuring conformance to label claim specifications. Purity testing identifies and quantifies impurities arising from synthesis, purification, or storage, ensuring product safety and efficacy.

Enantiomeric purity assessment represents a critical application for chiral APIs, given potential pharmacological and toxicological differences between enantiomers [58]. Chiral chromatography using specialized stationary phases or chiral mobile phase additives enables enantiomer separation and quantification.

Polymorphism characterization, while primarily addressed through spectroscopic and thermal techniques, benefits from

chromatographic methods for monitoring form conversions during processing and storage. Different polymorphic forms may exhibit different solubility and dissolution characteristics affecting chromatographic behavior [59].

5.2 Pharmaceutical Dosage Form Analysis

Finished pharmaceutical products present additional analytical challenges due to complex formulation matrices containing excipients, preservatives, colorants, and flavoring agents [60]. Validated chromatographic methods must demonstrate specificity in the presence of these potentially interfering components.

Tablet and capsule formulations typically require extraction procedures to solubilize the API and remove insoluble excipients before chromatographic analysis. Method development ensures complete extraction while avoiding degradation or transformation of the analyte [61].

Liquid dosage forms including solutions, suspensions, and emulsions require dilution and filtration before analysis. Preservative and antioxidant presence necessitates careful specificity evaluation to ensure accurate API quantification [62].

Parenteral formulations demand methods capable of detecting particulate matter, preservatives, and degradation products at trace levels, given stringent safety requirements for injectable products. Sterile product analysis requires appropriate aseptic technique and contamination control [63].

Controlled-release and modified-release formulations benefit from chromatographic methods coupled with dissolution testing, enabling correlation between in vitro release profiles and drug content uniformity [64].

Table 5: Applications of Chromatographic Methods in Different Dosage Forms

Dosage Form	Typical Chromatographic Method	Key Analytical Challenges	Sample Preparation
Tablets	RP-HPLC with UV detection	Excipient interference, content uniformity	Extraction, filtration, dilution
Capsules	RP-HPLC with UV detection	Shell dissolution, content separation	Extraction, filtration
Oral solutions	RP-HPLC with UV detection	Preservatives, sweeteners, colorants	Dilution, filtration
Suspensions	RP-HPLC with UV detection	Homogeneity, particle size effects	Sonication, filtration
Injectables	RP-HPLC with UV/MS	Trace impurities, particulates, sterility	Dilution, sterile filtration
Transdermal patches	RP-HPLC with UV detection	Polymer matrix, adhesive interference	Extraction from matrix
Inhalers	RP-HPLC or GC	Propellants, uniformity of delivered dose	Special extraction procedures
Ophthalmic	RP-HPLC with UV detection	Preservatives, sterility requirements	Dilution, sterile filtration

5.3 Stability Studies

Stability-indicating chromatographic methods represent mandatory requirements for pharmaceutical registration and quality monitoring [65]. These methods must separate the intact API from degradation products formed under accelerated and long-term storage conditions, enabling assessment of drug stability and establishment of appropriate shelf life.

Forced degradation studies guide stability method development by generating potential degradation products. Exposing samples to acidic, basic, oxidative, thermal, and photolytic stress conditions reveals stability weaknesses and helps establish appropriate storage conditions [46].

Long-term stability studies at defined storage conditions (typically twenty-five degrees Celsius and sixty percent relative humidity or thirty degrees Celsius and sixty-five percent relative humidity for different climatic zones) employ validated stability-indicating methods to monitor API content and degradation product formation over time [66].

Accelerated stability studies at elevated temperature and humidity conditions predict shelf life and identify potential degradation pathways. Statistical analysis of stability data enables shelf-life estimation and supports regulatory submissions [67].

5.4 Impurity Profiling

Impurity profiling represents a critical aspect of pharmaceutical quality control, ensuring patient safety by identifying and controlling potentially harmful impurities [68]. Chromatographic methods provide the primary means for impurity detection, quantification, and characterization.

Process-related impurities including starting materials, intermediates, reagents, and by-products require monitoring to ensure manufacturing process control and product consistency. Degradation products arising during storage require identification and qualification per regulatory guidelines [55].

6. Recent Advances and Trends

6.1 Green Chromatography

Environmental sustainability increasingly drives analytical method development through green chemistry principles. Green chromatography aims to reduce environmental impact

by minimizing hazardous solvent consumption, energy usage, and waste generation while maintaining analytical performance [75].

Solvent selection represents the primary focus of green chromatography initiatives. Replacing toxic solvents like chloroform and dichloromethane with less hazardous alternatives including ethanol, isopropanol, and acetone reduces environmental and health risks [76]. Aqueous methods further minimize organic solvent usage.

Column miniaturization through capillary and micro-bore formats dramatically reduces solvent consumption, often achieving ninety percent reductions compared to conventional columns while maintaining separation quality [77]. These formats additionally reduce waste disposal costs and environmental footprint.

Solvent recycling and recovery systems capture organic mobile phases for purification and reuse, significantly reducing solvent purchasing costs and disposal volumes. Modern instrumentation increasingly incorporates these capabilities as standard features [78].

Table 6: Green Chemistry Principles Applied to Chromatographic Method Development

Green Chemistry Principle	Implementation in Chromatography	Benefits	Examples
Waste prevention	Miniaturized columns, reduced injection volumes	70-90% solvent reduction	Capillary LC, micro-bore columns
Safer solvents	Replace toxic solvents with benign alternatives	Reduced toxicity, easier disposal	Ethanol instead of methanol, water instead of acetonitrile
Energy efficiency	Lower flow rates, ambient temperature analysis	Reduced energy consumption	Room temperature methods, optimized flow rates
Design for degradation	Use biodegradable mobile phase additives	Reduced environmental persistence	Biodegradable buffers
Real-time analysis	Online monitoring, reduced sample processing	Waste prevention, faster results	Process analytical technology (PAT)
Accident prevention	Reduced use of high-pressure systems	Enhanced safety	Ambient pressure methods

6.2 Miniaturized Techniques

Miniaturization trends encompass reduced instrument size, sample volumes, and reagent consumption. Microfluidic and lab-on-a-chip technologies integrate sample preparation, separation, and detection onto miniaturized platforms, enabling portable analysis with minimal resource requirements [79].

Nano-liquid chromatography operates with nanoliter-per-minute flow rates and nano-bore columns, providing exceptional mass sensitivity for limited sample quantities. These systems prove particularly valuable for bioanalytical applications involving precious biological samples [80].

Portable chromatographic instruments bring laboratory capabilities to field settings, enabling point-of-care testing, environmental monitoring, and quality control in resource-limited settings. Battery-powered instruments with wireless data transmission facilitate real-time analysis and decision-making [81].

6.3 Artificial Intelligence and Chemometrics

Artificial intelligence (AI) and machine learning algorithms revolutionize method development and data analysis [82]. Predictive modeling based on limited experimental data accelerates optimization by identifying optimal conditions without exhaustive experimentation.

Chemometric techniques including principal component analysis (PCA) and partial least squares (PLS) regression extract meaningful information from complex chromatographic data sets. These approaches facilitate pattern recognition, outlier detection, and multivariate calibration [83].

Automated method development platforms integrate robotics, AI algorithms, and chromatographic instrumentation, enabling unattended optimization of separation conditions. These systems evaluate hundreds of experimental conditions, identifying optimal methods far more efficiently than manual approaches [84].

Quality control applications increasingly employ AI for peak integration, impurity identification, and specification conformance assessment. Machine learning algorithms trained on historical data improve accuracy and consistency compared to manual data processing [85].

6.4 Fast and Cost-Effective Methods

Economic pressures and high-throughput requirements drive development of rapid analytical methods. Ultra-fast separations achieved through short columns, elevated temperatures, and optimized mobile phases reduce analysis times from thirty minutes to under five minutes without compromising separation quality [86].

Monolithic columns with continuous porous structures enable high flow rates and rapid separations while maintaining efficiency. These columns prove particularly valuable for high-throughput screening and quality control applications processing hundreds of samples daily [87].

Core-shell particle technology combines solid cores with porous shells, providing efficiency approaching sub-two-micron particles while generating lower back pressure compatible with conventional HPLC systems. This technology enables method improvements without expensive system upgrades [88].

7. Challenges and Limitations

7.1 Instrumentation Cost

Advanced chromatographic instrumentation represents significant capital investment, potentially limiting accessibility particularly in developing countries and smaller laboratories [90]. UPLC systems, mass spectrometers, and specialized detectors often cost several hundred thousand dollars, creating financial barriers to adoption.

Maintenance and operational costs including preventive maintenance, spare parts, column replacement, and mobile phase consumption contribute substantially to lifetime ownership costs. These ongoing expenses must be considered alongside initial capital investment when evaluating analytical capabilities [91].

Qualified technical personnel requirements represent additional resource considerations. Operating, maintaining, and troubleshooting sophisticated chromatographic systems demands specialized training and experience, potentially limiting implementation in settings with limited technical infrastructure [92].

7.2 Method Reproducibility

Achieving consistent method performance across different instruments, laboratories, and analysts presents ongoing challenges [93]. Minor differences in instrumentation, column characteristics, reagent quality, and environmental conditions can affect chromatographic behavior, potentially compromising method transferability.

Column-to-column variability, even from the same manufacturer and batch, introduces potential reproducibility issues. Establishing appropriate system suitability criteria and acceptance limits helps ensure adequate performance regardless of minor column variations [94].

Instrument-to-instrument differences in dwell volume, dispersion, temperature control, and detector response require careful consideration during method development. Building adequate robustness into methods minimizes performance variations across different instruments [95].

7.4 Regulatory Constraints

Navigating regulatory requirements across different jurisdictions presents challenges for global pharmaceutical companies [98]. While ICH guidelines provide harmonization, regional variations and interpretations create complexity in method development and validation.

Regulatory changes including evolving impurity guidelines, elemental impurity requirements, and nitrosamine contamination concerns necessitate method updates and revalidation, consuming significant resources and time [99].

Demonstrating method equivalence during transfers or modifications requires extensive validation studies and regulatory submissions, potentially delaying product launches or quality control operations [100].

8. Future Perspectives

8.1 Emerging Technologies

Emerging chromatographic technologies promise enhanced performance, sustainability, and accessibility. Supercritical fluid chromatography (SFC) using carbon dioxide as mobile phase offers green alternatives for chiral and achiral separations with reduced environmental impact [101].

Two-dimensional liquid chromatography (2D-LC) provides unprecedented peak capacity for complex samples by employing orthogonal separation mechanisms in two dimensions. These systems excel in impurity profiling, metabolite identification, and complex mixture analysis [102].

Ion mobility spectrometry coupled with chromatography adds an additional separation dimension based on molecular shape and charge, enhancing peak capacity and specificity beyond conventional approaches [103].

8.2 Sustainable Analytical Methods

Sustainability initiatives will increasingly shape analytical method development through reduced environmental footprint and resource consumption [104]. Solvent-free or minimal-solvent techniques including solid-phase microextraction and direct injection methods minimize waste generation.

Energy-efficient instrumentation incorporating LED light sources, optimized thermal management, and low-power electronics reduces operational energy consumption and carbon footprint. Solar-powered portable instruments may enable off-grid analytical capabilities [105].

Circular economy principles applied to analytical laboratories include solvent recycling, column regeneration, and waste

valorization, transforming analytical waste streams into valuable resources [106].

8.3 Integration with Automation and Artificial Intelligence

Future analytical laboratories will increasingly integrate automation, robotics, and artificial intelligence for autonomous operation [107]. Self-optimizing chromatographic systems continuously adjust parameters based on real-time performance monitoring, maintaining optimal separation without operator intervention.

Predictive maintenance enabled by machine learning algorithms monitors instrument performance parameters, identifying potential failures before they occur and minimizing unplanned downtime. These systems optimize maintenance scheduling and parts inventory management [108].

Remote operation and cloud-based data management enable distributed analytical networks where centralized experts support multiple sites, optimizing resource utilization and expertise distribution. Real-time data sharing facilitates rapid decision-making and quality monitoring across pharmaceutical supply chains [109].

Digital twin technology creating virtual replicas of chromatographic systems enables method development simulation, risk assessment, and training without consuming physical resources. These digital models accelerate method development and technology transfer [110].

9. Conclusion

Chromatographic methods remain indispensable tools for pharmaceutical analysis, providing essential capabilities for drug development, quality control, and regulatory compliance. The continuous evolution of pharmaceutical products and regulatory expectations necessitates ongoing innovation in analytical methodology. This review has comprehensively examined principles, practices, and emerging trends in chromatographic method development for pharmaceutical applications.

Modern chromatographic techniques including HPLC, UPLC, GC, and hyphenated methods offer versatile platforms accommodating diverse analytical requirements. Systematic method development approaches incorporating quality by design principles and experimental design methodologies enable efficient optimization while ensuring robustness and regulatory acceptability. Rigorous validation following ICH guidelines provides confidence in method reliability and fitness for purpose.

Applications spanning bulk drug analysis, formulation testing, stability studies, impurity profiling, and bioanalytical quantification demonstrate the breadth of chromatographic utility in pharmaceutical sciences. Recent advances including green chromatography, miniaturization, and artificial intelligence integration promise enhanced sustainability, efficiency, and accessibility.

References

- [1] Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography. 3rd ed. Hoboken: John Wiley & Sons; 2010.
- [2] Ahuja S, Dong MW. Handbook of Pharmaceutical Analysis by HPLC. Amsterdam: Elsevier; 2005.
- [3] International Conference on Harmonisation. ICH Q2(R1) Validation of Analytical Procedures: Text and Methodology. Geneva: ICH; 2005.
- [4] Plotka-Wasyłka J. A new tool for the evaluation of the analytical procedure: Green Analytical Procedure Index. *Talanta*. 2018;181:204-209.
- [5] Rajalahti T, Kvalheim OM. Multivariate data analysis in pharmaceuticals: A tutorial review. *International Journal of Pharmaceutics*. 2011;417(1-2):280-290.
- [6] Watson DG. Pharmaceutical Analysis: A Textbook for Pharmacy Students and Pharmaceutical Chemists. 3rd ed. Edinburgh: Churchill Livingstone; 2012.
- [7] Kazakevich Y, LoBrutto R. HPLC for Pharmaceutical Scientists. Hoboken: John Wiley & Sons; 2007.
- [8] Tiwari G, Tiwari R. Bioanalytical method validation: An updated review. *Pharmaceutical Methods*. 2010;1(1):25-38.
- [9] Moldoveanu SC, David V. Selection of the HPLC Method in Chemical Analysis. Amsterdam: Elsevier; 2017.
- [10] Dejaegher B, Vander Heyden Y. Experimental designs and their recent advances in set-up, data interpretation, and analytical applications. *Journal of Pharmaceutical and Biomedical Analysis*. 2011;56(2):141-158.
- [11] Meyer VR. Practical High-Performance Liquid Chromatography. 5th ed. Chichester: John Wiley & Sons; 2010.
- [12] Snyder LR, Glajch JL, Kirkland JJ. Practical HPLC Method Development. 2nd ed. New York: Wiley-Interscience; 1997.
- [13] Dong MW. Modern HPLC for Practicing Scientists. Hoboken: John Wiley & Sons; 2006.
- [14] Swartz ME. UPLC: An Introduction and Review. *Journal of Liquid Chromatography and Related Technologies*. 2005;28(7-8):1253-1263.
- [15] Taleuzzaman M, Ali S, Gilani SJ, Imam SS, Hafeez A. Ultra Performance Liquid Chromatography (UPLC): A Review. *Austin Journal of Analytical and Pharmaceutical Chemistry*. 2015;2(6):1056.
- [16] Fekete S, Guilleme D. Ultra-high-performance liquid chromatography for the characterization of therapeutic proteins. *TrAC Trends in Analytical Chemistry*. 2014;63:76-84.
- [17] McNair HM, Miller JM. Basic Gas Chromatography. 2nd ed. Hoboken: John Wiley & Sons; 2009.
- [18] Poole CF. Gas Chromatography. Amsterdam: Elsevier; 2012.
- [19] Sherma J, Fried B. Handbook of Thin-Layer Chromatography. 3rd ed. New York: Marcel Dekker; 2003.
- [20] Bose A. HPTLC method development and validation: An overview. *Journal of Pharmaceutical Science and Technology*. 2011;3(2):590-597.
- [21] Niessen WMA. Liquid Chromatography-Mass Spectrometry. 3rd ed. Boca Raton: CRC Press; 2006.

- [22] Ardrey RE. Liquid Chromatography-Mass Spectrometry: An Introduction. Chichester: John Wiley & Sons; 2003.
- [23] Sparkman OD, Penton Z, Kitson FG. Gas Chromatography and Mass Spectrometry: A Practical Guide. 2nd ed. Amsterdam: Academic Press; 2011.
- [24] Dolan JW. Temperature selectivity in reversed-phase high performance liquid chromatography. *Journal of Chromatography A*. 2002;965(1-2):195-205.
- [25] Gritti F, Guiochon G. The current revolution in column technology: How it began, where is it going? *Journal of Chromatography A*. 2012;1228:2-19.
- [26] Neue UD. HPLC Columns: Theory, Technology, and Practice. New York: Wiley-VCH; 1997.
- [27] Fanali S, Haddad PR, Poole CF, Riekkola ML. Liquid Chromatography: Applications. 2nd ed. Amsterdam: Elsevier; 2017.
- [28] Schoenmakers PJ. Optimization of Chromatographic Selectivity: A Guide to Method Development. Amsterdam: Elsevier; 1986.
- [29] Snyder LR, Kirkland JJ, Glajch JL. Practical HPLC Method Development. 2nd ed. New York: John Wiley & Sons; 1997.
- [30] Dolan JW, Snyder LR, Djordjevic NM, Hill DW, Waeghe TJ. Reversed-phase liquid chromatographic separation of complex samples by optimizing temperature and gradient time. *Journal of Chromatography A*. 1999;857(1-2):1-20.
- [31] Roses M. Determination of the pH of binary mobile phases for reversed-phase liquid chromatography. *Journal of Chromatography A*. 2004;1037(1-2):283-298.
- [32] McCalley DV. Effect of temperature and flow-rate on analysis of basic compounds in high-performance liquid chromatography using a reversed-phase column. *Journal of Chromatography A*. 2000;902(2):311-321.
- [33] Neue UD, Serowik E, Iraneta P, Alden BA, Walter TH. Universal procedure for the assessment of the reproducibility and the classification of silica-based reversed-phase packings. *Journal of Chromatography A*. 1999;849(1):87-100.
- [34] García-Alvarez-Coque MC, Torres-Lapasió JR, Baeza-Baeza JJ. Models and objective functions for the optimisation of selectivity in reversed-phase liquid chromatography. *Analytica Chimica Acta*. 2006;579(2):125-145.
- [35] Olsen BA. Hydrophilic interaction chromatography using amino and silica columns for the determination of polar pharmaceuticals and impurities. *Journal of Chromatography A*. 2001;913(1-2):113-122.
- [36] Bartle KD, Myers P. Theory and operation of fluorescence detectors for HPLC. *Journal of Chromatography A*. 2001;916(1-2):3-23.
- [37] Trathnigg B. Determination of MWD and chemical composition of polymers by chromatographic techniques. *Progress in Polymer Science*. 1995;20(4):615-650.
- [38] Vehovec T, Obreza A. Review of operating principle and applications of the charged aerosol detector. *Journal of Chromatography A*. 2010;1217(10):1549-1556.
- [39] Hibbert DB. Experimental design in chromatography: A tutorial review. *Journal of Chromatography B*. 2012;910:2-13.
- [40] Bezerra MA, Santelli RE, Oliveira EP, Villar LS, Escaleira LA. Response surface methodology (RSM) as a tool for optimization in analytical chemistry. *Talanta*. 2008;76(5):965-977.
- [41] Peraman R, Bhadrara K, Reddy YP. Analytical quality by design: A tool for regulatory flexibility and robust analytics. *International Journal of Analytical Chemistry*. 2015;2015:868727.
- [42] Kormány R, Molnár I, Rieger HJ. Exploring better column selectivity choices in ultra-high performance liquid chromatography using Quality by Design principles. *Journal of Pharmaceutical and Biomedical Analysis*. 2013;80:79-88.
- [43] Ermer J, Miller JHM. Method Validation in Pharmaceutical Analysis: A Guide to Best Practice. Weinheim: Wiley-VCH; 2005.
- [44] Shabir GA. Validation of high-performance liquid chromatography methods for pharmaceutical analysis. *Journal of Chromatography A*. 2003;987(1-2):57-66.
- [45] Alsante KM, Ando A, Brown R, Ensing J, Hatajik TD, Kong W, Tsuda Y. The role of degradant profiling in active pharmaceutical ingredients and drug products. *Advanced Drug Delivery Reviews*. 2007;59(1):29-37.
- [46] Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs—A review. *Journal of Pharmaceutical Analysis*. 2014;4(3):159-165.
- [47] Huber L. Validation of analytical methods: Review and strategy. *LC-GC International*. 1998;11(2):96-105.
- [48] Swartz ME, Krull IS. Analytical Method Development and Validation. New York: Marcel Dekker; 1997.
- [49] Patil KR, Rao GK, Patil PR, Patil SS. Analytical method development and validation: A concise review. *Journal of Pharmacy Research*. 2013;7(9):806-812.
- [50] Bhavsar DS, Patel BN, Patel CN. RPHPLC method development and validation for simultaneous estimation of paracetamol, phenylephrine hydrochloride, caffeine and cetirizine hydrochloride in tablet dosage form. *Journal of Chemical and Pharmaceutical Research*. 2011;3(2):322-330.
- [51] Taverniers I, De Loose M, Van Bockstaele E. Trends in quality in the analytical laboratory. II. Analytical method validation and quality assurance. *TrAC Trends in Analytical Chemistry*. 2004;23(8):535-552.
- [52] Gonzalez AG, Herrador MA. A practical guide to analytical method validation, including measurement uncertainty and accuracy profiles. *TrAC Trends in Analytical Chemistry*. 2007;26(3):227-238.
- [53] Horwitz W. Protocol for the design, conduct and interpretation of method-performance studies. *Pure and Applied Chemistry*. 1995;67(2):331-343.
- [54] Shrivastava A, Gupta VB. Methods for the determination of limit of detection and limit of quantitation of the analytical methods. *Chronicles of Young Scientists*. 2011;2(1):21-25.
- [55] Guidance for Industry: Q3A(R2) Impurities in New Drug Substances. US Food and Drug Administration; 2008.

- [56] Youden WJ, Steiner EH. Statistical Manual of the Association of Official Analytical Chemists. Washington DC: AOAC; 1975.
- [57] Siddiqui MR, AlOthman ZA, Rahman N. Analytical techniques in pharmaceutical analysis: A review. *Arabian Journal of Chemistry*. 2017; 10: S1409-S1421.
- [58] Ward TJ, Baker BA. Chiral separations. *Analytical Chemistry*. 2008;80(12):4363-4372.
- [59] Brittain HG. Polymorphism in Pharmaceutical Solids. 2nd ed. New York: Informa Healthcare; 2009.
- [60] Karmarkar S, Garber R, Genchanok Y, George S, Yang X, Hammond R. Quality by design (QbD) based development of a stability indicating HPLC method for drug and impurities. *Journal of Chromatographic Science*. 2011;49(6):439-446.
- [61] Singh S, Handa T, Narayanam M, Sahu A, Junwal M, Shah RP. A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products. *Journal of Pharmaceutical and Biomedical Analysis*. 2012; 69: 148-173.
- [62] Patel SA, Patel NM. Stability indicating RP-HPLC method development and validation for simultaneous estimation of rabeprazole and levosulpiride in pharmaceutical dosage form. *Journal of Taibah University for Science*. 2014;8(4):265-274.
- [63] Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. *Journal of Immunological Methods*. 2004;289(1-2):1-16.
- [64] Yuksel N, Kanik AE, Baykara T. Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and -independent methods. *International Journal of Pharmaceutics*. 2000;209(1-2):57-67.
- [65] Guideline IHT. Stability testing of new drug substances and products Q1A (R2). International Conference on Harmonization. 2003.
- [66] Ngwa G. Forced degradation studies: An essential tool for the formulation development of antiretroviral drugs. *Journal of Analytical and Bioanalytical Techniques*. 2012; 3: 144.
- [67] Zhou D, Porter WR. Stability studies of pharmaceuticals by differential scanning calorimetry. *American Pharmaceutical Review*. 2003;6(3):26-32.
- [68] Nageswara Rao R, Nagaraju V. An overview of the recent trends in development of HPLC methods for determination of impurities in drugs. *Journal of Pharmaceutical and Biomedical Analysis*. 2003;33(3):335-377.
- [69] Teasdale A, Elder DP, Nims RW. ICH M7: Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. International Conference on Harmonization; 2014.
- [70] Lewen N, Mathew S, Schenkenberger M, Raglione T. A rapid ICP-MS screen for heavy metals in pharmaceutical compounds. *Journal of Pharmaceutical and Biomedical Analysis*. 2004;35(4):739-752.
- [71] Novakova L, Vlckova H. A review of current trends and advances in modern bio-analytical methods: chromatography and sample preparation. *Analytica Chimica Acta*. 2009;656(1-2):8-35.
- [72] Chambers E, Wagrowski-Diehl DM, Lu Z, Mazzeo JR. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. *Journal of Chromatography B*. 2007;852(1-2):22-34.
- [73] Rogatsky E, Stein D. Evaluation of matrix effect and chromatography efficiency: New parameters for validation of method development. *Journal of the American Society for Mass Spectrometry*. 2005;16(11):1757-1759.
- [74] Mullangi R, Srinivas NR. Clopidogrel: Review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies. *Biomedical Chromatography*. 2009;23(1):26-41.
- [75] Koel M, Kaljurand M. *Green Analytical Chemistry*. Cambridge: Royal Society of Chemistry; 2010.
- [76] Gałuszka A, Migaszkowski ZM, Konieczka P, Namieśnik J. Analytical Eco-Scale for assessing the greenness of analytical procedures. *TrAC Trends in Analytical Chemistry*. 2012; 37: 61-72.
- [77] Blue LE, Franklin EG, Godinho JM, Grinias JP, Grinias KM, Lunn DB, Moore SM. Recent advances in capillary ultrahigh pressure liquid chromatography. *Journal of Chromatography A*. 2017; 1523: 17-39.
- [78] Welch CJ, Wu N, Biba M, Hartman R, Brkovic T, Gong X, Helmy R, Schafer W, Cuff J, Pirzada Z, Zhou L. Greening analytical chromatography. *TrAC Trends in Analytical Chemistry*. 2010;29(7):667-680.
- [79] Gałuszka A, Migaszkowski ZM, Namieśnik J. Moving your laboratories to the field: Advantages and limitations of the use of field portable instruments in environmental sample analysis. *Environmental Research*. 2015; 140: 593-603.
- [80] Jorgenson JW. Capillary liquid chromatography at ultrahigh pressures. *Annual Review of Analytical Chemistry*. 2010; 3: 129-150.
- [81] Gamoh K, Nakashima K. A new portable analyzer using lateral-flow immunochromatography for the rapid determination of PCBs in insulating oil. *Journal of AOAC International*. 2008;91(6):1390-1395.
- [82] Kormány R, Molnár I, Rieger HJ. Exploring better column selectivity choices in ultra-high performance liquid chromatography using Quality by Design principles. *Journal of Pharmaceutical and Biomedical Analysis*. 2013; 80: 79-88.
- [83] Brereton RG. *Chemometrics for Pattern Recognition*. Chichester: John Wiley & Sons; 2009.
- [84] Snyder LR, Dolan JW. *High-Performance Gradient Elution: The Practical Application of the Linear-Solvent-Strength Model*. Hoboken: John Wiley & Sons; 2007.
- [85] Wilschefske SC, Baxter MR. Inductively coupled plasma mass spectrometry: introduction to analytical aspects. *Clinical Biochemist Reviews*. 2019;40(3):115-133.
- [86] Fekete S, Kohler I, Rudaz S, Guillaume D. Importance of instrumentation for fast liquid chromatography in pharmaceutical analysis. *Journal of Pharmaceutical and Biomedical Analysis*. 2014; 87: 105-119.

- [87] Guiochon G. Monolithic columns in high-performance liquid chromatography. *Journal of Chromatography A*. 2007;1168(1-2):101-168.
- [88] Hayes R, Ahmed A, Edge T, Zhang H. Core-shell particles: Preparation, fundamentals and applications in high- performance liquid chromatography. *Journal of Chromatography A*. 2014; 1357: 36-52.
- [89] Edge AM, Shillingford S, Smith C, Payne R, Wilson ID. Temperature as a variable in liquid chromatography: Development of a model for the separation of model basic drugs using coupled columns of Hypercarb and Hypersil C18. *Journal of Chromatography A*. 2006;1132(1-2):206-210.
- [90] Lunn G. *HPLC Methods for Pharmaceutical Analysis*. Hoboken: John Wiley & Sons; 2000.
- [91] Carr PW, Stoll DR, Wang X. Perspectives on recent advances in the speed of high-performance liquid chromatography. *Analytical Chemistry*. 2011;83(6):1890-1900.
- [92] Huxley VA. Current best practices in graduate student training: The unique role and value of interdisciplinary approaches. *Advances in Physiology Education*. 2012;36(4):257-264.
- [93] Dispas A, Desfontaine V, Andri B, Lebrun P, Kotoni D, Clarke A, Vargas Guillemette P, Losacco GL, Morbidelli M, Guillaume D, Veuthey JL, Hubert P, Fillet M. "Quality by Design" approach for the analysis of impurities in pharmaceutical drug products and drug substances. *TrAC Trends in Analytical Chemistry*. 2018; 101: 24-33.
- [94] Vervoort N, Daemen D, Török G. Performance evaluation of evaporative light scattering detection and charged aerosol detection in reversed phase liquid chromatography. *Journal of Chromatography A*. 2008;1189(1-2):92-100.
- [95] Fekete S, Beck A, Fekete J, Guillaume D. Method development for the separation of monoclonal antibody charge variants in cation exchange chromatography, Part I: Salt gradient approach. *Journal of Pharmaceutical and Biomedical Analysis*. 2015;102: 33-44.
- [96] Taylor PJ. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. *Clinical Biochemistry*. 2005;38(4):328-334.
- [97] Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A. Bioanalytical method validation—a revisit with a decade of progress. *Pharmaceutical Research*. 2000;17(12):1551-1557.
- [98] Bansal SK, Layloff T, Bush ED, Hamilton M, Hankinson EA, Landy JS. Qualification of analytical instruments for use in the pharmaceutical industry: A scientific approach. *AAPS PharmSciTech*. 2004;5(1):22-31.
- [99] Teasdale A, Delaney E, Eyley SC, Jacq K, Taylor-Worth K, Lipczynski A, Reif V, Elder DP, Facchine KL, Golec S, Oestrich RS. A detailed study of sulfonate ester formation under relevant stress conditions: Likelihood and importance to the pharmaceutical industry. *Organic Process Research & Development*. 2010;14(4):999-1007.
- [100] Martin GP, Barnett KL, Burgess C, Curry PD, Ermer J, McB Miller J, Nethercote P, Strickland T. Lifecycle management of analytical procedures: Method development, procedure performance qualification, and procedure performance verification. *Pharmaceutical Forum*. 2013;39(5):1-11.
- [101] West C, Lesellier E. A unified classification of stationary phases for packed column supercritical fluid chromatography. *Journal of Chromatography A*. 2008;1191(1-2):21-39.
- [102] Donato P, Cacciola F, Mondello L, Dugo P. Comprehensive chromatographic separations in proteomics. *Journal of Chromatography A*. 2011;1218(49):8777-8790.
- [103] Laphorn C, Pullen F, Chowdhry BZ. Ion mobility spectrometry-mass spectrometry (IMS-MS) of small molecules: separating and assigning structures to ions. *Mass Spectrometry Reviews*. 2013;32(1):43-71.
- [104] Armenta S, Garrigues S, de la Guardia M. Green analytical chemistry. *TrAC Trends in Analytical Chemistry*. 2008;27(6):497-511.
- [105] Keith LH, Gron LU, Young JL. Green analytical methodologies. *Chemical Reviews*. 2007;107(6):2695-2708.
- [106] Anastas PT, Warner JC. *Green Chemistry: Theory and Practice*. New York: Oxford University Press; 1998.
- [107] Leardi R. Experimental design in chemistry: A tutorial. *Analytica Chimica Acta*. 2009;652(1-2):161-172.
- [108] Cela R, Ordoñez EY, Quintana JB, Rodil R. Chemometric-assisted method development in reversed-phase liquid chromatography. *Journal of Chromatography A*. 2013; 1287: 2-22.
- [109] Huber L. *Validation and qualification in analytical laboratories*. 2nd ed. New York: Informa Healthcare; 2007.
- [110] García-Muñoz S, Dolph S, Buenabad-Chávez H. Predictive performance of the design space and control space. *Journal of Process Control*. 2010;20(10):1193-1202.